The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Preliminary data on mezigdomide plus dexamethasone and bortezomib in R/R multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, comments on mezigdomide (CC-92480), a novel cereblon E3 ligase modulator (CELMoD) currently being assessed in combination with standard treatments in CC-92480-MM-002, a Phase I/II study in patients with relapsed/refractory (R/R) multiple myeloma (NCT03989414). Dr Richardson explains that the mechanism of action of mezigdomide is different from that of immunomodulatory drugs (IMiDs). Preliminary data from the cohort treated with a combination of mezigdomide, dexamethasone and bortezomib in a dose-escalated fashion is promising, with a response rate (RR) of 74% and manageable side effects. Further results on the efficacy of this combination, as well as on the combination of carfilzomib and mezigdomide are eagerly awaited. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
